Contract analysis

I. Executive Summary On October 15, 2024, the law firm of Zalcourt Archer & Cole LLP, acting through its lead partner Rebecca Whitmore, delivered a formal demand letter to Penterra Pharmaceuticals Corp. ("Penterra" or the "Company") on behalf of Veridian Biosciences, Inc. ("Veridian") and the Stockholder Representative, David Ng of Crestline Ventures, LP. The demand letter asserts that Penterra's termination of the S

II. Summary of Veridian's Demand Letter A. Factual Allegations in the Demand Letter The demand letter from Zalcourt Archer & Cole LLP provides a detailed factual narrative framed from Veridian's perspective. We summarize the principal factual allegations below, together with our initial observations regarding their accuracy and significance. Transaction Overview. The demand letter recites that on June 10, 2024, Pente

1. Breach of Contract (SPA). Veridian's primary claim is that Penterra wrongfully terminated the SPA under § 8.1(d) because no material adverse effect occurred within the meaning of the SPA's MAE definition (§ 1.1). Veridian contends that the Buyer's closing conditions under §§ 7.2(a) and 7.2(b) remained satisfied or, at a minimum, remained capable of being satisfied prior to the Outside Date of December 10, 2024. By

2. Specific Performance (SPA § 10.12). Veridian invokes SPA § 10.12, which expressly grants the Sellers the right to seek specific performance to compel the Buyer to consummate the closing of the transaction if all closing conditions have been satisfied or waived. Veridian argues that all closing conditions were in fact satisfied (or capable of satisfaction), and that the Court of Chancery should order Penterra to cl

3. Alternative: Expectation Damages. If specific performance is unavailable or impracticable, Veridian claims entitlement to expectation damages — measured as the difference between the $900,000,000 purchase price and the current fair market value of Veridian's equity. Veridian asserts that its equity value has been "substantially diminished" as a direct and proximate result of the failed transaction and the resultin

III. Analysis of Veridian's Breach of Contract Claim A. Framework: Penterra's Right to Terminate Under SPA § 8.1(d) The threshold question in this dispute is whether Penterra validly exercised its right to terminate the SPA under § 8.1(d). The resolution of this question determines whether Penterra is liable for breach of contract or whether the termination was rightful and Penterra has no further obligations under t

Section 8.1(d) of the SPA provides, in relevant part: This Agreement may be terminated by Buyer at any time prior to the Closing if (i) any of the conditions set forth in Section 7.2 shall have become incapable of being satisfied prior to the Outside Date, and (ii) the failure of such condition to be satisfied is not the result of a breach by Buyer of any representation, warranty, covenant, or agreement of Buyer set

Section 7.2(a) — Bring-Down of Representations and Warranties. The representations and warranties of the Sellers set forth in this Agreement shall be true and correct in all respects (without giving effect to any materiality or Material Adverse Effect qualifiers therein) as of the Closing Date as though made on and as of the Closing Date (except to the extent expressly made as of an earlier date, in which case as of

Section 7.2(b) — No Material Adverse Effect. Since the date of this Agreement, there shall not have occurred any Material Adverse Effect. Penterra's termination letter, dated September 30, 2024 and delivered to Veridian and the Stockholder Representative by overnight courier, specifically invoked both § 7.2(a) and § 7.2(b). The letter stated that the occurrence of a Material Adverse Effect rendered both conditions in

1. The SPA Definition (§ 1.1). The MAE definition in § 1.1 of the SPA is a negotiated provision that largely follows market-standard formulations. It provides, in relevant part: "Material Adverse Effect" means any event, change, development, occurrence, condition, or effect that, individually or in the aggregate, has had or would reasonably be expected to have a material adverse effect on (a) the business, results of

2. Application of Marlowe Asset Management-2 Clinical Data. The clinical data from the Marlowe Asset Management-2 Phase II trial, as presented in the DMC analysis report dated August 14, 2024, constitute the factual foundation for Penterra's MAE determination. The data reveal the following: Safety Profile — Cytokine Release Syndrome. Grade ≥3 cytokine release syndrome was observed in 23.4% of patients in the VRD-4187

3. FDA Partial Clinical Hold. The FDA's imposition of a partial clinical hold on VRD-4187 (IND 154832), effective August 22, 2024, is an independent and significant fact supporting Penterra's MAE determination. The hold was imposed in direct response to the seven treatment-related deaths observed in the Marlowe Asset Management-2 trial and the CRS safety signal. Veridian's characterization of the partial clinical hol

4. Durational Significance Under Delaware Law. The concept of "durational significance" is central to the Delaware framework for evaluating MAE claims. Under the foundational case of Akorn, Inc. v. Fresenius Kabi AG, 2018 WL 4719347 (Del. Ch. Oct. 1, 2018), aff'd, 198 A.3d 724 (Del. 2018), and the extensive body of Chancery Court precedent that preceded it, a material adverse effect must be measured against the long-

1. General Industry Conditions Carveout. Veridian's demand letter argues that the clinical trial results for VRD-4187 fall within the MAE carveout for "conditions affecting the biotechnology or pharmaceutical industries generally." The theory appears to be that clinical trial risk is inherent and endemic to the biotechnology industry, and that the failure of a clinical-stage compound to demonstrate an adequate safety

2. Pandemic Carveout. The SPA includes a specific carveout for pandemics, including COVID-19 and any similar public health emergencies. The demand letter makes a passing reference to this carveout, but does not articulate any specific causal nexus between the COVID-19 pandemic (or any other pandemic or public health emergency) and the VRD-4187 safety data. Assessment. The pandemic carveout is inapplicable to the pres

3. Disproportionate Impact Exception. Even if Veridian could somehow bring the clinical data within one of the MAE carveouts — which, as discussed above, it cannot — the carveouts in the SPA are subject to a disproportionate impact exception. Specifically, carveouts (i) through (vi) do not apply to the extent that the relevant event, change, or condition "has had or would reasonably be expected to have a disproportio

IV. Analysis of Veridian's Specific Performance Claim A. Contractual Right Under SPA § 10.12

Section 10.12 of the SPA provides a negotiated specific performance remedy for the Sellers. The relevant language reads: The parties agree that irreparable damage would occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached. Each party shall be entitled to seek specific performance of the terms hereof, including an injuncti

V. Analysis of Veridian's Expectation Damages Claim A. Measure of Damages In the alternative to specific performance, Veridian will seek expectation damages. Under Delaware law, expectation damages for breach of a stock purchase agreement are measured by the benefit of the bargain — i.e., the difference between the contract price and the fair market value of the seller's equity at the time of the breach. See, e.g., S

VI. Analysis of Reverse Termination Fee Demand ($45,000,000) A. SPA Structure for Reverse Termination Fee The SPA includes a reverse termination fee provision (§ 8.3(b)) pursuant to which Penterra, as Buyer, is obligated to pay a fee of $45,000,000 to the Stockholder Representative (for distribution to the Sellers) upon the occurrence of certain specified events. The reverse termination fee was calculated at 5% of th

VII. Procedural Considerations A. Forum and Governing Law SPA § 10.6 designates the Court of Chancery of the State of Delaware as the exclusive forum for any action, suit, or proceeding arising out of or relating to the SPA or the transactions contemplated thereby. Section 10.5 provides that the SPA is governed by and construed in accordance with the laws of the State of Delaware, without regard to conflicts-of-law p